Advanced search
Publication Cover
Leukemia & Lymphoma Volume 46, 2005 - Issue 7
Submit an article Journal homepage
78
Views
15
CrossRef citations to date
0
Altmetric
Letter to the Editor

Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma

Asher Chanan-Khan Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USACorrespondence[email protected]
&
Kena C Miller Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
Pages 1103-1104 | Published online: 03 Aug 2009

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Asher Chanan-Khan, Kena C. Miller, Laurie Musial, Swaminathan Padmanabhan, Jihnhee Yu, Sikander Ailawadhi, Taimur Sher, Alice Mohr, Zale P. Bernstein, Maurice Barcos, Mehul Patel, Dan Iancu, Kelvin Lee & Myron S. Czuczman. (2009) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia & Lymphoma 50:7, pages 1096-1101.
Read now
Muralikrishnan Srikanth, Faith E Davies & Gareth J Morgan. (2008) An update on drug combinations for treatment of myeloma. Expert Opinion on Investigational Drugs 17:1, pages 1-12.
Read now

Articles from other publishers (13)

Matthew J. Streetly, Jacob Laubach, Paul Richardson & Stephen A. Schey. 2013. Myeloma. Myeloma 144 166 .
Efstathios Kastritis, Antonio Palumbo & Meletios A. Dimopoulos. (2009) Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology 46:2, pages 143-157.
Crossref
M.V. Mateos & J.F. San Miguel. (2007) Bortezomib in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, pages 701-715.
Crossref
Sheeba K. Thomas, Tiffany A. Richards & Donna M. Weber. (2007) Lenalidomide in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, pages 717-735.
Crossref
Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Suzanne R. Hayman, Susan Geyer, Brian Kabat, Steven R. Zeldenrust, Shaji Kumar, Philip R. Greipp, Rafael Fonseca, John A. Lust, Stephen J. Russell, Robert A. Kyle, Thomas E. Witzig, P. Leif Bergsagel, A. Keith Stewart & S. Vincent Rajkumar. (2007) Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings 82:10, pages 1179-1184.
Crossref
Sheeba Thomas, Tiffany Richards & Donna M. Weber. 2007. Multiple Myeloma: Translational and Emerging Therapies. Multiple Myeloma: Translational and Emerging Therapies 141 168 .
Jian HOU & Wang Michael. (2007) Current status and future directions in the treatment of multiple myeloma. Chinese Medical Journal 120:19, pages 1651-1654.
Crossref
Asher A. Chanan-KhanJonathan L. KaufmanJayesh MehtaPaul G. Richardson, Kena C. MillerSagar LonialNikhil C. Munshi, Robert Schlossman, Joseph TarimanSeema Singhal. (2006) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:6, pages 2604-2606.
Crossref
M. Teresa Cibeira, Laura Rosiñol, Laia Ramiro, Jordi Esteve, Montserrat Torrebadell & Joan Bladé. (2006) Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. European Journal of Haematology 77:6, pages 486-492.
Crossref
Miriam M. Kleiter, Daohai Yu, Lenore A. Mohammadian, Nelsen Niehaus, Ivan Spasojevic, Linda Sanders, Benjamin L. Viglianti, Pavel S. Yarmolenko, Marlene Hauck, Neil A. Petry, Terence Z. Wong, Mark W. Dewhirst & Donald E. Thrall. (2006) A Tracer Dose of Technetium-99m–Labeled Liposomes Can Estimate the Effect of Hyperthermia on Intratumoral Doxil Extravasation. Clinical Cancer Research 12:22, pages 6800-6807.
Crossref
Ashraf Badros, Olga Goloubeva, Robert Fenton, Aaron P. Rapoport, Gorgun Akpek, Carolynn Harris, Kathleen Ruehle, Sandra Westphal & Barry Meisenberg. (2006) Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma 7:3, pages 210-216.
Crossref
Tommaso Caravita, Paolo de Fabritiis, Antonio Palumbo, Sergio Amadori & Mario Boccadoro. (2006) Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nature Clinical Practice Oncology 3:7, pages 374-387.
Crossref
Rajni Sinha, Jonathan L. Kaufman & Sagar Lonial. (2006) Novel Treatment Approaches for Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma 6:4, pages 281-288.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.